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Introduction 
Intralesional corticosteroids are an effective 
treatment for various dermatological and non-
dermatological disorders owing to their ability to 
achieve high local concentrations and prolonged 
depot effects with minimal systemic absorption [1]. 
Despite their efficacy, they are associated with 
various, uncommon, local adverse events including; 
hypopigmentation, hyperpigmentation, dermal or 
subcutaneous atrophy, alopecia, infection, 
ulceration, and localized dystrophic calcification [1]. 
Atrophy and hypopigmentation most commonly 
remain localized to sites of injection. However, 
outward radiation in a linear, streaky pattern has 
been reported and is termed 
“perilesional/perilymphatic hypopigmentation or 
atrophy [2].” We report a case of this rare adverse 
event.  
Case Synopsis 
A 77-year-old man with hypothyroidism presented 
to dermatology clinic with an expanding, 
leukodermic patch overlying the right elbow. Eight 
months prior to presentation, the patient had 
undergone a single injection of triamcinolone 
acetonide (40mg/ml) for the treatment of lateral 
epicondylitis. Two months after the injection, he 
noticed a slowly expansile, white patch near the 
injection site. Examination revealed a 
hypopigmented patch with peripheral linear 
streaking and underlying atrophy of the right 
extensor elbow. There was no evidence of 
perifollicular repigmentation. Wood lamp 
examination revealed enhancement with central 
hypopigmentation and a peripheral pigmentary 
gradient (Figure 1). A biopsy was not performed. The 
patient was treated with tacrolimus ointment to 
attempt to halt progression. 
Abstract 
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Figure 1. A) Hypopigmented patch with peripheral linear 
streaking and underlying atrophy of the right extensor elbow. B) 
Wood lamp examination revealed enhancement with central 
hypopigmentation with a peripheral pigmentary gradient. 
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Case Discussion 
The pathogenesis of corticosteroid-induced 
hypopigmentation is not well understood, but 
previous studies suggest inhibition of melanocyte 
function without loss of melanocytes may contribute 
[2]. Corticosteroids may prevent prostaglandin or 
cytokine production in various epidermal cells and 
may suppress release of secretory metabolic 
products from melanocytes without causing their 
destruction [1]. The mechanism of linear 
hypopigmentation and atrophy is also unknown [2]. 
Prior studies theorize the spread of corticosteroid 
crystals along cutaneous lymphatic vessels as the 
underlying cause after alphazurine 2 G (Patent Blue) 
was injected into an atrophic lesion and 
subsequently tracked along the associated 
lymphatic vessel [3]. Extension of hypopigmentation 
perilesionally has been reported up to two feet from 
site of injection, possibly related to additive or 
synergistic effects of hyaluronidase in breaking 
connective tissue barriers and facilitating absorption 
into lymphatic vessels [4]. Evaluation of more 
patients with this complication is needed before any 
definitive conclusions are made. Treatment of 
corticosteroid-induced perilymphatic hypopig-
mentation and atrophy is limited. Reports of 
spontaneous resolution range from months-to-
years, yet some cases persist despite cessation of 
steroid treatment [2]. There is one case report of 
successful treatment with a 308nm excimer light that 
showed near complete repigmentation after 6 
treatments [5]. Another study reported significant 
repigmentation after a single treatment with 
10,600nm wavelength fractional carbon dioxide 
laser followed by immediate, intentional, solar 
exposure intended to up-regulate melanocytic 
activity [6]. Evaluation of more patients with this rare 
event are needed to further determine effective 
treatment options.  
 
Conclusion 
Perilesional/perilymphatic hypopigmentation or 
atrophy is a rare adverse event to intralesional 
corticosteroids. Although the pathogenesis is not 
entirely known, it may involve the spread of 
corticosteroid crystals along cutaneous lymphatic 
vessels [3]. The duration of the hypopigmentation 
and/or atrophy is variable with limited data on 
available treatment options. 
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